Effectiveness and economic evaluation for vancomycin pharmaceutical care based on therapeutic drug monitoring

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028903

Enrollment

Unknown

Registered

2020-01-06

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infectious diseases (MRSA)

Interventions

experimental group :pharmaceutical care

control group:Nil

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients with MRSA infection or highly suspected MRSA infection; 2. Treated with vancomycin; 3. Creatinine and serum cystatin C were measured before vancomycin use.

Exclusion criteria

Exclusion criteria: 1. Aged = 1 week; 4. Urine volume >= 4000ml/d; 5. Combination drugs with significant renal toxicity (e.g. Aminoglycosides, amphotericin B).

Design outcomes

Primary

Measure	Time frame
Clinical efficiency;VI-AKI incidence rate;cost;	—

Secondary

Measure	Time frame
the rate of vancomycin trough concentrations within the desired target range;	—

Countries

China

Contacts

Public ContactMing Hu

West China Medical College of Sichuan University

huming@scu.edu.cn+86 028 85501387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026